Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28463538.
- Also identified by DOI 10.2214/AJR.17.18264 and PMC identifier 5565155.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This article reviews recent developments in targeted radionuclide therapy (TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-resistant metastatic prostate cancer and discusses challenges and opportunities in this field. TRT has been employed since the first radioiodine thyroid treatment almost 75 years ago. Progress in the understanding of the complex underlying biology of cancer and advances in radiochemistry science, multimodal imaging techniques including the concept of "see and treat" within the framework of theranostics, and universal traction with the notion of precision medicine have all contributed to a resurgence of TRT.
Medical subject headings
- Bone Neoplasms
- Iodine Radioisotopes
- Liver Neoplasms
- Multimodal Imaging
- Neuroendocrine Tumors
- Precision Medicine
- Prostatic Neoplasms